[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-hypertension-complicating-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-hypertension-complicating-pregnancy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100389856","phase-3-chronic-hypertension-and-acetyl-salicylic-acid-in-pregnancy-100389856",false,"NCT04356326","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial.","CHASAP","Inclusion Criteria:\n\n* Pregnant patient between 10 and 19 weeks of gestation + 6 days\n* Chronic hypertension, whether treated or not, know before pregnancy or diagnosed before randomization\n* Singleton pregnancy\n* Signed the written informed consent\n* Affiliation to social security\n\nExclusion Criteria:\n\n* ---Medical history requiring anticoagulation (antiphospholipid syndrome, deep vein thromboembolic disease, pulmonary embolism, atherothrombosis, patient with mechanical heart valves),\n* Patient receiving aspirin for another indication outside pregnancy,\n* Patient with significant proteinuria (\\> 300mg\u002F24 hours or a proteinuria\u002Fcreatininuria ratio ≥ 30mg\u002Fmmol),\n* Active bleeding,\n* History of severe PE with delivery \\\u003C 34 weeks of gestation,\n* Hypersensitivity to salicylates such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs),\n* Platelet count lower than 100,000 cells\u002Fmicroliter (dosage less than 6 months old),\n* Hemostasis disorders, including hemophilia (with thrombocytopenia)\n* Any constitutional or acquired hemorrhagic disease, (including digestive hemorrhages, history of hemorrhagic stroke and thrombocytopenia\n* Human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus positive serum,\n* Patient included in another interventional study which could interfere with the results of the study,\n* Age \\\u003C18 years old,\n* Women under the protection of justice,\n* Patients with psychiatric follow-up, poor understanding of French or cognitive problems,\n* Duodenal ulcer,\n* Severe renal impairment,\n* Severe hepatic insufficiency,\n* Severe cardiac impairment,\n* Gout,\n* Patients with known glucose-6-phosphate dehydrogenase deficiency,","FEMALE","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150 mg\u002Fday started before 20 weeks of gestation in the prevention on maternal and fœtal complications in pregnant women with chronic hypertension.",[27,28,29,30,31,32],"Chronic Hypertension Complicating Pregnancy","Pre-Eclampsia","Intrauterine Growth Restriction","Aspirin","Perinatal Death","Placental Abruption","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2021-02-15",{"date":41,"type":21},"2030-02",{"name":43,"class":44},"Centre Hospitalier Intercommunal Creteil","OTHER",20]